Spyre Therapeutics Announces Grants of Inducement Awards

Got story updates? Submit your updates here. ›

Spyre Therapeutics, a clinical-stage biotechnology company focused on inflammatory bowel disease and rheumatic diseases, announced that its independent Compensation Committee approved the grant of stock options to purchase an aggregate of 70,200 shares of Spyre's common stock to five non-executive employees as equity inducement awards.

Why it matters

The stock options were granted as an incentive to help Spyre attract and retain key talent as the company continues to advance its pipeline of long-acting antibody therapies. Equity compensation is a common practice in the biotech industry to motivate and reward employees.

The details

The stock options have a 10-year term and an exercise price of $48.90 per share, which was the closing price of Spyre's stock on the grant date. The options will vest over four years, with 25% vesting on the first anniversary of the employee's start date and the remaining 75% vesting monthly thereafter.

• The stock options were approved on April 1, 2026.
• The options were granted to the employees on April 3, 2026.